Mode of progression in smoldering multiple myeloma : a study of 406 patients
© 2024. The Author(s)..
The approach to patients with high-risk smoldering multiple myeloma (SMM) varies among clinicians; while some advocate early intervention, others reserve treatment at progression to multiple myeloma (MM). We aimed to describe the myeloma-defining events (MDEs) and clinical presentations leading to MM diagnosis among SMM patients seen at our institution. We included 406 patients diagnosed with SMM between 2013-2022, seen at Mayo Clinic, Rochester, MN. The 2018 Mayo 20/2/20 criteria were used for risk stratification. Median follow-up was 3.9 years. Among high-risk patients who did not receive treatment in the SMM phase (n = 71), 51 progressed by last follow-up; the MDEs included: bone lesions (37%), anemia (35%), hypercalcemia (8%), and renal failure (6%); 24% met MM criteria based on marrow plasmacytosis (≥60%) and/or free light chain ratio (>100); 45% had clinically significant MDEs (hypercalcemia, renal insufficiency, and/or bone lesions). MM diagnosis was made based on surveillance labs/imaging(45%), testing obtained due to provider suspicion for progression (14%), bone pain (20%), and hospitalization/ED presentations due to MM complications/symptoms (4%). The presentation was undocumented in 14%. A high proportion (45%) of patients with high-risk SMM on active surveillance develop end-organ damage at progression. About a quarter of patients who progress to MM are not diagnosed based on routine interval surveillance testing.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Blood cancer journal - 14(2024), 1 vom: 17. Jan., Seite 9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abdallah, Nadine H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 18.01.2024 Date Revised 29.02.2024 published: Electronic UpdateOf: Res Sq. 2023 Oct 23;:. - PMID 37961238 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41408-024-00980-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367191792 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367191792 | ||
| 003 | DE-627 | ||
| 005 | 20240229234750.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240117s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41408-024-00980-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1311.xml |
| 035 | |a (DE-627)NLM367191792 | ||
| 035 | |a (NLM)38228628 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abdallah, Nadine H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mode of progression in smoldering multiple myeloma |b a study of 406 patients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.01.2024 | ||
| 500 | |a Date Revised 29.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateOf: Res Sq. 2023 Oct 23;:. - PMID 37961238 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a The approach to patients with high-risk smoldering multiple myeloma (SMM) varies among clinicians; while some advocate early intervention, others reserve treatment at progression to multiple myeloma (MM). We aimed to describe the myeloma-defining events (MDEs) and clinical presentations leading to MM diagnosis among SMM patients seen at our institution. We included 406 patients diagnosed with SMM between 2013-2022, seen at Mayo Clinic, Rochester, MN. The 2018 Mayo 20/2/20 criteria were used for risk stratification. Median follow-up was 3.9 years. Among high-risk patients who did not receive treatment in the SMM phase (n = 71), 51 progressed by last follow-up; the MDEs included: bone lesions (37%), anemia (35%), hypercalcemia (8%), and renal failure (6%); 24% met MM criteria based on marrow plasmacytosis (≥60%) and/or free light chain ratio (>100); 45% had clinically significant MDEs (hypercalcemia, renal insufficiency, and/or bone lesions). MM diagnosis was made based on surveillance labs/imaging(45%), testing obtained due to provider suspicion for progression (14%), bone pain (20%), and hospitalization/ED presentations due to MM complications/symptoms (4%). The presentation was undocumented in 14%. A high proportion (45%) of patients with high-risk SMM on active surveillance develop end-organ damage at progression. About a quarter of patients who progress to MM are not diagnosed based on routine interval surveillance testing | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Immunoglobulin Light Chains |2 NLM | |
| 700 | 1 | |a Lakshman, Arjun |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Shaji K |e verfasserin |4 aut | |
| 700 | 1 | |a Cook, Joselle |e verfasserin |4 aut | |
| 700 | 1 | |a Binder, Moritz |e verfasserin |4 aut | |
| 700 | 1 | |a Kapoor, Prashant |e verfasserin |4 aut | |
| 700 | 1 | |a Dispenzieri, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Gertz, Morie A |e verfasserin |4 aut | |
| 700 | 1 | |a Lacy, Martha Q |e verfasserin |4 aut | |
| 700 | 1 | |a Hayman, Suzanne R |e verfasserin |4 aut | |
| 700 | 1 | |a Buadi, Francis K |e verfasserin |4 aut | |
| 700 | 1 | |a Dingli, David |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Kourelis, Taxiarchis |e verfasserin |4 aut | |
| 700 | 1 | |a Warsame, Rahma |e verfasserin |4 aut | |
| 700 | 1 | |a Bergsagel, Leif |e verfasserin |4 aut | |
| 700 | 1 | |a Rajkumar, S Vincent |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood cancer journal |d 2011 |g 14(2024), 1 vom: 17. Jan., Seite 9 |w (DE-627)NLM219701628 |x 2044-5385 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:1 |g day:17 |g month:01 |g pages:9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41408-024-00980-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 1 |b 17 |c 01 |h 9 | ||